1-6 of 6
Adrian Senderowicz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Kristie A. Blum, Jeffrey G. Supko, Michael Maris, Ian W. Flinn, Andre H. Goy, Anas Younes, Suresh Bobba, Adrian Senderowicz, Sergey Efuni, Ronda Rippley, Jeremy S. Abramson
Journal: Blood
Blood (2021) 138 (Supplement 1): 1202.
https://doi.org/10.1182/blood-2021-150852
Published: 2021
Journal Articles

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Jennifer A Mertz, PhD, Patricia J Keller, PhD, Rosana D Meyer, MD, Oksana Zavidij, PhD, Jike Cui, PhD, Jean-Jacques Kiladjian, MD PhD, Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Moshe Talpaz, MD, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Ruben Mesa, MD, John Mascarenhas, MD, Adrian Senderowicz, MD, Gozde Colak, PhD, James Shao, MS, Katarina Luptakova, MD, Jeffrey S Humphrey, MD, Jing Wang, PhD, Patrick Trojer, PhD, Mohamed E Salama, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-138752
Published: 2020
Journal Articles

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Katarina Luptakova, MD, Jessica Christo, MA, Jing Wang, PhD, Jennifer A Mertz, PhD, Gozde Colak, PhD, James Shao, MS, Suresh Bobba, MD, Patrick Trojer, PhD, Adrian Senderowicz, MD, Jeffrey S Humphrey, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43.
https://doi.org/10.1182/blood-2020-140901
Published: 2020
Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 670.
https://doi.org/10.1182/blood-2019-127119
Published: 2019
Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 4164.
https://doi.org/10.1182/blood-2019-128211
Published: 2019
Journal Articles

A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF)

Marina Kremyanskaya, MD PhD, Ronald Hoffman, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Jennifer Mertz, PhD, Fiona Garner, PhD, Adrian Senderowicz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5481.
https://doi.org/10.1182/blood-2018-99-119157
Published: 2018